A Phase Ib Study of YHI-1702 in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase 1
Completed
- Conditions
- Chronic lymphocytic leukemia/small lymphocytic lymphoma
- Registration Number
- JPRN-jRCT2080224791
- Lead Sponsor
- Yakult Honsha Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Diagnosis of active CLL or SLL
- Disease that has progressed during or relapsed after at least one previous CLL/SLL therapy
- Measurable disease > 1.5 cm
- ECOG PS of 0 or 1
- Presence of adequate organ and bone-marrow functions
Exclusion Criteria
- History of Richter's transformation or prolymphocytic leukemia
- Known central nervous system lymphoma or leukemia
- Prior exposure to a PI3K inhibitor
- Unstable or severe uncontrolled medical condition
- Pregnant or lactating women
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method efficacy<br>ORR
- Secondary Outcome Measures
Name Time Method safety<br>efficacy<br>PFS<br>OS